Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
2(40%)
Results Posted
100%(3 trials)

Phase Distribution

Ph phase_3
3
60%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
3(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(3)

Detailed Status

Completed3
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 33 (100.0%)

Trials by Status

active_not_recruiting120%
completed360%
recruiting120%

Recent Activity

2 active trials
Showing 5 of 5
recruiting

A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine

NCT06087627
active_not_recruiting

Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)

NCT03992417
completedphase_3

Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)

NCT03620747
completedphase_3

Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps

NCT02898454
completedphase_3

A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps

NCT02912468

Clinical Trials (5)

Showing 5 of 5 trials
NCT06087627

A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine

Recruiting
NCT03992417

Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)

Active Not Recruiting
NCT03620747Phase 3

Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)

Completed
NCT02898454Phase 3

Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps

Completed
NCT02912468Phase 3

A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5